MORF-057, an oral α4β7 integrin inhibitor candidate, holds potential for treating inflammatory bowel diseases
Phase 2b EMERALD-2 clinical trial of MORF-057 expected to begin mid-year 2022
Read more at globenewswire.comhello world
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
